Quoin Pharmaceuticals Ltd. Cash and Restricted Cash
Quoin Pharmaceuticals Ltd. (QNRX) had Cash and Restricted Cash of $3.85 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.85M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.12M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.82M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.83M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $3.85M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $3.12M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $3.82M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $1.83M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.67M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $3.82M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $3.62M 10-Q · filed 2026-08-14 |
| 2024-09-30 | $3.12M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $2.85M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $1.83M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $2.40M 10-K · filed 2026-03-26 |
| 2023-09-30 | $3.16M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $4.76M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $3.37M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $2.86M 10-K · filed 2025-03-13 |
| 2022-09-30 | $5.25M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $2.69M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $5.19M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $7.48M 10-K · filed 2024-03-14 |
| 2021-09-30 | $652.79K 6-K · filed 2022-11-10 |
| 2021-06-30 | $1.72M 6-K · filed 2022-08-18 |
| 2020-12-31 | $323.83K 10-K · filed 2023-03-15 |
| 2018-12-31 | $40.00 20-F · filed 2022-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |